Well, if we needed further proof that Argenica were working in...

Well, if we needed further proof that Argenica were working in the right space, we have this statement posted by The Guardian ...

"The number of people in the UK experiencing a stroke will increase more than 50% to 151,000 a year by 2035, costing
the NHS and the economy £75bn in healthcare and lost productivity, stark new projections suggest."

Any reasonable improvement shown by ARG-007 in this current trial should grab the headlines across the world.

Interesting times girls and boys, interesting times.

As noted recently by the Perron Institute, about a possible rival (NA-1) ...

"Experiments by the team at Perron Institute have consistently found ARG-007 to be superior to NA-1, and critical new data
has demonstrated that the D-enantiomer of ARG-007 (i.e. peptide synthesised with D-arginine as opposed to L-arginine) to
be resistant to degradation by plasmin. This has important implications for ARG-007 to be potentially a much more useful
drug when used in combination with standard stroke care."

Possibly time for me to 'top up' again.

Opinion only of course.